IRIS
CIPRIANI, PAOLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.515
AS - Asia 7.272
EU - Europa 6.854
SA - Sud America 761
AF - Africa 109
OC - Oceania 26
Continente sconosciuto - Info sul continente non disponibili 17
Totale 27.554
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.349
SG - Singapore 3.253
IE - Irlanda 1.630
RU - Federazione Russa 1.526
CN - Cina 1.479
HK - Hong Kong 753
TR - Turchia 720
IT - Italia 697
BR - Brasile 650
VN - Vietnam 623
SE - Svezia 613
DE - Germania 599
UA - Ucraina 407
GB - Regno Unito 394
FR - Francia 351
FI - Finlandia 239
NL - Olanda 154
IN - India 123
CA - Canada 98
JP - Giappone 80
BE - Belgio 46
ZA - Sudafrica 43
AR - Argentina 40
MX - Messico 40
BD - Bangladesh 38
ES - Italia 35
PL - Polonia 33
LT - Lituania 29
ID - Indonesia 23
CZ - Repubblica Ceca 22
IQ - Iraq 20
PK - Pakistan 18
AU - Australia 17
EC - Ecuador 17
VE - Venezuela 16
MA - Marocco 15
AT - Austria 14
EU - Europa 14
KR - Corea 14
SA - Arabia Saudita 14
JO - Giordania 13
CO - Colombia 12
DZ - Algeria 10
PH - Filippine 10
TN - Tunisia 10
UZ - Uzbekistan 10
GR - Grecia 9
PY - Paraguay 8
AL - Albania 7
AZ - Azerbaigian 7
CH - Svizzera 7
EG - Egitto 7
IL - Israele 7
JM - Giamaica 7
KZ - Kazakistan 7
MY - Malesia 7
NP - Nepal 7
NZ - Nuova Zelanda 7
AE - Emirati Arabi Uniti 6
CL - Cile 6
MK - Macedonia 6
RO - Romania 6
TH - Thailandia 6
BO - Bolivia 5
KE - Kenya 5
LB - Libano 5
PE - Perù 5
TW - Taiwan 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
PT - Portogallo 4
CI - Costa d'Avorio 3
GE - Georgia 3
HN - Honduras 3
IR - Iran 3
KW - Kuwait 3
LU - Lussemburgo 3
MM - Myanmar 3
NI - Nicaragua 3
PS - Palestinian Territory 3
RS - Serbia 3
SN - Senegal 3
AO - Angola 2
BB - Barbados 2
BG - Bulgaria 2
CR - Costa Rica 2
ET - Etiopia 2
HR - Croazia 2
KG - Kirghizistan 2
LV - Lettonia 2
NG - Nigeria 2
NO - Norvegia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
YT - Mayotte 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AG - Antigua e Barbuda 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
Totale 27.532
Salva come PNG Salva come JPEG
Città #
Singapore 1.777
Jacksonville 1.642
Dublin 1.624
Chandler 1.609
San Jose 1.240
Dallas 1.188
Ashburn 776
Hong Kong 742
Santa Clara 634
Boardman 579
Izmir 404
The Dalles 334
New York 325
Moscow 294
Nanjing 273
Wilmington 246
Lawrence 235
Princeton 235
San Mateo 225
Beijing 221
Ho Chi Minh City 200
Ann Arbor 196
Lauterbourg 152
Los Angeles 145
L'aquila 129
Hanoi 128
Amsterdam 120
Milan 104
Nanchang 100
Hefei 89
Council Bluffs 85
Dearborn 85
Woodbridge 82
Munich 81
Seattle 77
Tokyo 73
São Paulo 70
Shenyang 65
Helsinki 57
Des Moines 56
Shanghai 50
Verona 50
L’Aquila 48
Frankfurt am Main 47
Kunming 46
Columbus 43
Mountain View 43
Brussels 42
Hebei 42
Orem 42
Jiaxing 41
Jinan 35
Rome 35
Dong Ket 34
Tianjin 33
Changsha 31
Johannesburg 31
Lappeenranta 30
Montreal 29
Phoenix 29
Stockholm 29
Zhengzhou 29
Houston 28
Chicago 27
Haiphong 27
Norwalk 27
Brooklyn 25
Chennai 25
Pune 25
Warsaw 25
Da Nang 24
Philadelphia 24
London 22
Manchester 21
Pescara 21
New Delhi 20
Atlanta 19
Denver 19
Guangzhou 19
Hangzhou 19
Rio de Janeiro 19
San Francisco 19
Brno 18
Ningbo 18
Ankara 17
Falkenstein 17
Assago 16
Belo Horizonte 16
Boston 15
Kitzingen 15
Toronto 15
Brasília 14
Mexico City 14
Amman 13
Mumbai 13
Nuremberg 13
Poplar 13
Jakarta 12
Charlotte 11
Guarulhos 11
Totale 18.252
Salva come PNG Salva come JPEG
Nome #
Studio dell’espressione della chemochina SDF-1 e del suo recettore CXCR4 nella cute e nelle cellule endoteliali microvascolari di pazienti affetti da sclerosi sistemica (SSc). 194
Aumento dei linfociti circolanti gamma-delta Vdelta1+ in corso di malattie infiammatorie intestinali 180
Blocking Jak/STAT signalling using tofacitinib inhibits angiogenesis in experimental arthritis 175
Unenhanced Cardiac Magnetic Resonance may improve detection and prognostication of an occult heart involvement in asymptomatic patients with systemic sclerosis 170
Guidelines for biomarkers in autoimmune rheumatic diseases - evidence based analysis 158
FRI0613 H-ferritin and pro-inflammatory cytokines are increased in the bone marrow of adult patients affected by macrophage activation syndrome 157
Perivascular cells in diffuse cutaneous systemic sclerosis overexpress activated ADAM12 and are involved in myofibroblast transdifferentiation and development of fibrosis 154
Evaluating the multivisceral involvement on adult-onset Still’s disease to retrieve imaging-based differences in patients with and without macrophage activation syndrome: results from a single-centre observational study 154
Role of CD248 molecule as potential regulator of trans-differentiation toward myofibroblasts of perivascular stromal cells in systemic sclerosis patients 153
Macitentan inhibits the transforming growth factor-β profibrotic action, blocking the signaling mediated by the ETR/TβRI complex in systemic sclerosis dermal fibroblasts 152
Mesenchymal stem cells (MSCs) from scleroderma patients (SSc) preserve their immunomodulatory properties although senescent and normally induce T regulatory cells (Tregs) with a functional phenotype: implications for cellular-based therapy. 151
IL-1β at the crossroad between rheumatoid arthritis and type 2 diabetes: may we kill two birds with one stone? 149
H-ferritin and proinflammatory cytokines are increased in the bone marrow of patients affected by macrophage activation syndrome 149
Prognostic factors of adult onset Still’s disease: analysis of 100 cases in 3 tertiary referral centers 148
The emerging role of IL-1 inhibition in patients affected by rheumatoid arthritis and diabetes 147
The role of extracellular matrix components in angiogenesis and fibrosis: Possible implication for Systemic Sclerosis. 145
Linfociti T Gamma-Delta (G/D) in pazienti con malattie infiammatorie intestinali (IBD) 138
Interleukin-9 Overexpression and Th9 Polarization Characterize the Inflamed Gut, the Synovial Tissue, and the Peripheral Blood of Patients With Psoriatic Arthritis 138
The CD68+/H-ferritin+ cells colonize the lymph nodes of the patients with adult onset Still's disease and are associated with increased extracellular level of H-ferritin in the same tissue: Correlation with disease severity and implication for pathogenesis 138
association of pathogenic and regulatory B-cell subsets with clinical and histological features in primary Sjogren's syndrome. 137
PTP4A1 promotes TGFβ signaling and fibrosis in systemic sclerosis 136
Pro-inflammatory properties of H-ferritin on human macrophages, ex vivo and in vitro observations 136
Prognostic factors of macrophage activation syndrome, at the time of diagnosis, in adult patients affected by autoimmune disease: Analysis of 41 cases collected in 2 rheumatologic centers 135
H-ferritin and CD68(+) /H-ferritin(+) monocytes/macrophages are increased in the skin of adult-onset Still's disease patients and correlate with the multi-visceral involvement of the disease 135
Monocytes from patients with rheumatoid arthritis and type 2 diabetes mellitus display an increased production of interleukin (IL)-1β via the nucleotide-binding domain and leucine-rich repeat containing family pyrin 3(NLRP3)-inflammasome activation: a possible implication for therapeutic decision in these patients. 133
Where are we going in the management of interstitial lung disease in patients with systemic sclerosis? 133
Short-term effectiveness of guselkumab in psoriatic arthritis patients and axial involvement: results from a real-life multicentre cohort 131
Cardiovascular disease in primary sjögren’s syndrome 130
Different operators and histologic techniques in the assessment of germinal center-like structures in primary Sjögren's syndrome minor salivary glands 130
Impaired Cav-1 expression in SSc mesenchymal cells upregulates VEGF signaling: a link between vascular involvement and fibrosis 129
T Regulatory and T Helper 17 Cells in Primary Sjögren's Syndrome: Facts and Perspectives. 129
Adult-onset Still's disease: evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 127
Mesenchymal stromal cells and rheumatic diseases: new tools from pathogenesis to regenerative therapies. 127
Advances in immunopathogenesis of macrophage activation syndrome during rheumatic inflammatory diseases: toward new therapeutic targets? 126
Stromal Cell-derived Factor 1 in Cardiac and Autoimmune Disease 125
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study 125
Epidermal Growth Factor Like-domain 7 and miR-126 are abnormally expressed in diffuse Systemic Sclerosis fibroblasts 125
Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences 125
Macrophage activation syndrome in Still's disease: analysis of clinical characteristics and survival in paediatric and adult patients. 124
Interleukin (IL)-22 receptor 1 is over-expressed in primary Sjogren's syndrome and Sjögren-associated non-Hodgkin lymphomas and is regulated by IL-18. 122
Endothelial progenitor cells: Are they displaying a function in autoimmune disorders? 121
Increased cardiovascular events and subclinical atherosclerosis in rheumatoid arthritis patients: 1 year prospective single centre study 121
Interleukin-32 in systemic sclerosis, a potential new biomarker for pulmonary arterial hypertension 121
Dissecting the clinical heterogeneity of adult-onset Still's disease, results from a multi-dimensional characterisation and stratification 121
Increased level of H-ferritin and its imbalance with L-ferritin, in bone marrow and liver of patients with adult onset Still's disease, developing macrophage activation syndrome, correlate with the severity of the disease. 120
Linking myofibroblast generation and microvascular alteration: The role of CD248 from pathogenesis to therapeutic target (Review) 120
Tofacitinib May Inhibit Myofibroblast Differentiation from Rheumatoid-Fibroblast-like Synoviocytes Induced by TGF-β and IL-6 119
Impairment of endothelial cell differentiation from bone marrow-derived mesenchymal stem cells: new insight into the pathogenesis of systemic sclerosis 119
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 118
Stem cell therapies for systemic sclerosis 118
SENESCENT BONE MARROW DERIVED MESENCHYMAL STEM CELLS (MSC) ARE PRONE TO RECOVER DURING SSC 117
Jejunoileal bypass as the main procedure in the onset of immune-related conditions: the model of BADAS. 117
Adipocytokines in Rheumatoid Arthritis: The Hidden Link between Inflammation and Cardiometabolic Comorbidities 117
Comment on 'Where are we going in the management of interstitial lung disease in patients with systemic sclerosis?' 116
SDF-1/CXCR4 system in microvascular endothelial cells and skin from patients affected by systemic sclerosi 116
Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies a very early cardiac involvement in systemic sclerosis patients of recent onset 116
Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort 116
Circulating gamma/delta T lymphocytes from systemic sclerosis (SSc) patients display a T helper (Th) 1 polarization 115
Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis 115
The Endothelial-mesenchymal Transition in Systemic Sclerosis Is Induced by Endothelin-1 and Transforming Growth Factor-β and May Be Blocked by Macitentan, a Dual Endothelin-1 Receptor Antagonist. 115
Derivation and validation of four patient clusters in Still’s disease, results from GIRRCS AOSD-study group and AIDA Network Still Disease Registry 114
 T cells in placenta and skin: their different functions may support the paradigm of microchimerism in systemic sclerosi 114
Peripheral blood mononuclear cells of patients with systemic sclerosis produce increased amounts of interleukin 6, but not transforming growth factor beta 1. 114
Mesenchymal stem cells of Systemic Sclerosis patients, derived from different sources, show a profibrotic microRNA profiling 114
Impaired Endothelium-Mesenchymal Stem Cells Cross-talk in Systemic Sclerosis: a Link Between Vascular and Fibrotic Features. 114
Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? 114
Combined approach to the initial stage raynaud’s phenomenon diagnosis by means of dynamic digital telehermograpy, capillaroscopy and pletismography. Preliminary findings. 113
Searching for a good model for systemic sclerosis: The molecular profile and vascular changes occurring in UCD-200 chickens strongly resemble the early phase of human systemic sclerosis 113
Cytokine profile, ferritin and multi-visceral involvement characterize macrophage activation syndrome during adult-onset Still's disease 112
Efficacy of inhibition of IL-1 in patients with rheumatoid arthritis and type 2 diabetes mellitus: two case reports and review of the literature. 112
International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)?: The unmet needs and the clinical grey zone in autoimmune disease management. 112
GAMMA/DELTA T CELL APOPTOSIS IN SYSTEMIC SCLEROSIS PATIENTS 112
Parenchymal lung disease in adult onset Still's disease: An emergent marker of disease severity - Characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort of patients 112
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis. 112
Methotrexate in rheumatoid arthritis: optimizing therapy among different formulations. Current and emerging paradigms 111
Blocking CD248 molecules in perivascular stromal cells of patients with systemic sclerosis strongly inhibits their differentiation toward myofibroblasts and proliferation: A new potential target for antifibrotic therapy 111
Gamma-delta T cells are not involved in the natural and antibody-dependent cytotoxicity of peripheral blood mononuclear cells in inflammatory bowel disease. 111
Interstitial lung disease in systemic sclerosis: current and future treatment. 110
Resistance to apoptosis in circulating alpha/beta and gamma/delta T lymphocytes from patients with systemic sclerosis 109
The -670G>A polymorphism in the FAS gene promoter region influences the susceptibility to systemic sclerosis. 108
Interleukin-9 and T helper type 9 cells in rheumatic diseases 108
Managing Adult-onset Still's disease: The effectiveness of high-dosage of corticosteroids as first-line treatment in inducing the clinical remission. Results from an observational study 108
IL-1 inhibition improves insulin resistance and adipokines in rheumatoid arthritis patients with comorbid type 2 diabetes: An observational study 108
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al 108
Persistence of C-reactive protein increased levels and high disease activity are predictors of cardiovascular disease in patients with axial spondyloarthritis 107
DUO Registry Group. Functional impairment of systemic scleroderma patients with digital ulcerations: results from the DUO Registry. 107
EFFICACY AND SAFETY OF RITUXIMAB TREATMENT IN EARLY PRIMARY SJOGREN'S SYNDROME: A CLINICAL, HISTOLOGICAL AND MOLECULAR STUDY 107
EFFICACY AND SAFETY OF RITUXIMAB ORIGINATOR AND BIOSIMILAR IN PRIMARY SJOGREN'S SYNDROME IN A REAL-LIFE SETTING 107
The IL1-like cytokine IL33 and its receptor ST2 are abnormally expressed in the affected skin and visceral organs of patients with systemic sclerosis 107
The assessment of atlantoaxial joint involvement in patients with rheumatoid arthritis, results from an observational "real-life" study 106
Long-term Safety of Rituximab in Primary Sjögren Syndrome: The Experience of a Single Center 106
Prevalence of type 2 diabetes and impaired fasting glucose in patients affected by rheumatoid arthritis: Results from a cross-sectional study. 106
CARDIAC MAGNETIC RESONANCE IMAGING WITH PHARMACOLOGICAL STRESS PERFUSION IN ASYMPTOMATIC PATIENTS WITH SYSTEMIC SCLEROSIS 106
Myofibroblast Cells Expression of CD248 May Contribute to Exacerbate Microvascular Damage during Systemic Sclerosis 106
Severe COVID-19, Another Piece in the Puzzle of the Hyperferritinemic Syndrome. An Immunomodulatory Perspective to Alleviate the Storm. 106
Variations of neuronal nitric oxide synthase in systemic sclerosis skin 105
The Role of IL-1β in the Bone Loss during Rheumatic Diseases 105
Increase of circulating gamma/delta T lymphocytes in the peripheral blood of patients affected by active inflammatory bowel disease 105
Macrophage activation syndrome in patients affected by adult-onset still disease: Analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort 105
ASSESSING PRO-INFLAMMATORY PROPERTIES OF H-FERRITIN BY EX VIVO AND IN VITRO OBSERVATIONS 105
Totale 12.398
Salva come PNG Salva come JPEG
Categoria #
all - tutte 118.866
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 118.866
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021548 0 0 0 0 0 0 0 0 0 73 371 104
2021/20221.310 74 88 249 96 33 19 28 63 108 68 93 391
2022/20234.607 336 251 82 479 395 489 31 298 2.013 30 143 60
2023/20241.248 168 74 82 157 106 363 25 73 9 57 36 98
2024/20255.119 114 89 484 180 650 461 673 394 1.179 213 346 336
2025/20269.292 535 1.005 748 1.149 942 740 1.757 413 1.022 981 0 0
Totale 27.899